
Pure native aortic regurgitation (AR) remains a challenging and frequently undertreated valvular disease, associated with substantial morbidity and mortality. Surgical aortic valve repair or replacement remains the standard of care; however, many patients are older, frail, or at prohibitive surgical risk, creating an unmet need for less invasive therapeutic options. In this context, transcatheter aortic valve implantation (TAVI) has progressively emerged as a potential alternative. However, the application of TAVI in AR has historically been limited by the absence of annular and leaflet calcification, the presence of large and often noncircular annuli, and the resulting risks of transcatheter valve embolization or migration, residual paravalvular regurgitation, and conduction disturbances. This review summarizes contemporary evidence on TAVI for pure native AR, spanning early off-label experience with first-generation self-expanding and balloon-expandable valves to newer-generation platforms and dedicated devices. Recent observational studies and multicenter registries have shown meaningful improvements in procedural success, lower rates of residual AR and second valve implantation, and acceptable short- and mid-term mortality with contemporary off-label devices. Dedicated systems, including JenaValve Trilogy, J-Valve, and others, have further enhanced anchoring and sealing performance, achieving markedly lower rates of valve migration and significant residual regurgitation. Nonetheless, permanent pacemaker implantation remains a major limitation for several platforms. In parallel, the AURORA trial introduced an anatomy-guided strategy based on multidetector computed tomography classification and dual anchoring theory, suggesting that careful anatomical selection and optimized implantation planning may improve outcomes even with non-dedicated devices. Overall, TAVI has become a viable option for selected high-risk patients with severe symptomatic pure native AR and has now been incorporated into contemporary guidelines in this setting. Future progress will likely depend on further refinement of dedicated devices, reduction of conduction-related complications, and broader integration of patient-specific anatomical and biomechanical assessment to optimize device selection and implantation strategy.
This study aimed to review the contemporary literature on the health economics of minimally invasive cardiac surgery (MICS). MICS is being increasingly adopted worldwide. While the clinical and patient-reported outcomes of MICS have been established, uncertainty remains regarding the health economic aspect of MICS. This review aims to address that knowledge gap. This is a comprehensive narrative review of articles evaluating the health economics of MICS across various jurisdictions and healthcare systems. Electronic databases, including PubMed, Embase, and Scopus, were searched from inception through November 2025. Search terms included combinations of MICS, health economics, minimally invasive direct coronary artery bypass, mini-aortic valve replacement, mini-thoracotomy, hemi-sternotomy, aortic valve replacement, right anterior mini thoracotomy, robotic cardiac surgery, robot-assisted cardiac surgery, video-assisted cardiac surgery, and port-access cardiac surgery. Across procedure types, studies consistently demonstrated that high-volume, well-standardized MICS programs can achieve cost neutrality or cost savings, relative to conventional surgery, with reported hospital cost reductions ranging from approximately 9% for mini-aortic valve replacement to CAD 16,700 for minimally invasive mitral valve surgery. These savings are largely attributable to improved postoperative efficiency and reduced resource utilization. In contrast, centers with low surgical volumes or fragmented workflows often incur significantly higher costs per case and risk underutilizing expensive technologies, such as robotic systems. When implemented in well-resourced, experienced centers, MICS appears to be a promising, value-driven strategy for contemporary cardiac care. Health systems should consider centralizing MICS services to optimize capital investment and realize sustainable economic value, rather than distributing these resources broadly across lower-volume centers.
Background: Whether nocturnal ventricular tachyarrhythmias (VTAs) are associated with poorer long-term survival than daytime VTAs remains unclear. This study aimed to investigate the association between nocturnal VTAs and long-term survival, as well as the associated prognostic relevance. Methods: Implantable cardioverter-defibrillator (ICD) recipients from the Study of Home Monitoring System Safety and Efficacy in Cardiac Implantable Electronic Device-implanted Patients (SUMMIT) registry were retrospectively analyzed using data from home monitoring transmissions. Nocturnal VTAs were defined as episodes occurring between 22:00 and 05:59, whereas daytime VTAs were defined as those occurring during the remaining 16 hours (06:00–21:59). Results: Over a median follow-up of 61.7 months, 102 cardiac deaths and 187 deaths from any cause were recorded. Among 730 patients, 422 experienced VTAs, of whom 231 (54.7%) had nocturnal VTAs. Compared with patients without VTAs, those with nocturnal VTAs had a 62% higher risk of cardiac death (hazard ratio (HR), 1.62; 95% confidence interval (CI): 1.02–2.59; p = 0.041) and a 2.3-fold higher risk of all-cause mortality (HR, 2.30; 95% CI: 1.50–3.53; p < 0.001). Patients with nocturnal VTAs experienced more ICD shocks (77.9% [180/231] vs. 59.2% [113/191]; p < 0.001), more electrical storms (46.8% [108/231] vs. 9.4% [18/191]; p < 0.001), and a higher VTA burden (median, 1.36 [IQR, 3.44] vs. 0.59 [IQR, 1.01] episodes per year) than those with daytime-only VTAs. Elevated nighttime heart rate and reduced left ventricular ejection fraction (LVEF), as well as male sex and prior atrial fibrillation, were identified as independent risk factors for nocturnal VTAs. Conclusions: Nocturnal VTAs were not uncommon. Patients experiencing nocturnal VTAs had a higher risk of cardiac death and all-cause mortality. Monitoring the occurrence and timing of VTA episodes may be a useful tool for identifying high-risk patients. Clinical Trial Registration: ChiCTR-ONRC-13003695, https://www.chictr.org.cn/showproj.html?proj=5865.
Historically considered a “neglected” valvular disease, moderate-to-severe tricuspid regurgitation (TR) is now recognized as an important contributor to morbidity, mortality, and right-sided heart failure (HF). Natural history studies show that significant TR is frequently associated with left-sided valve disease, particularly mitral valve disease, and independently predicts poor outcomes as severity increases. The 2025 European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) Guidelines for the Management of Valvular Heart Disease place unprecedented emphasis on TR, elevating this condition from a secondary afterthought to a central element of comprehensive valvular therapy. This reflects an evolution of evidence over the past decade, underscored by increased diagnostic sensitivity through multimodal imaging and the development of novel therapeutic options. However, gaps in the existing evidence persist, and addressing these uncertainties will support future research. This paper provides a comprehensive review of the evidence on TR, incorporates updates from the latest European guidelines, focuses on the most relevant and controversial aspects of patient selection, and identifies key areas where knowledge is insufficient. Furthermore, this review revisits the historical foundations of tricuspid valve research, highlighting how several anatomical concepts fundamental to contemporary interventions were already described as early as the 17th century, underscoring the long-standing scientific interest in this once “forgotten” valve.